90 related articles for article (PubMed ID: 16949787)
1. Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.
Alaoui-Jamali MA
Biomed Pharmacother; 2006 Nov; 60(9):629-32. PubMed ID: 16949787
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
7. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
9. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
[TBL] [Abstract][Full Text] [Related]
10. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
12. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
13. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
[TBL] [Abstract][Full Text] [Related]
14. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of action of targeted therapies... and mechanisms of resistance].
Bergot E; Richard N; Zalcman G
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S180-7. PubMed ID: 18235412
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
Cohen S; Fleischmann R
Curr Opin Rheumatol; 2010 May; 22(3):330-5. PubMed ID: 20164774
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in pediatric malignancies.
Skolnik JM; Adamson PC
Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
[TBL] [Abstract][Full Text] [Related]
20. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.
Lee J; Ou SH
Discov Med; 2013 Jun; 15(85):333-41. PubMed ID: 23819947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]